Učitavanje...

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset fro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Adv Neurol Disord
Glavni autor: Khatri, Bhupendra O.
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2016
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784254/
https://ncbi.nlm.nih.gov/pubmed/27006700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616628766
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!